Search

Your search keyword '"Abasolo L"' showing total 35 results
Start Over Author "Abasolo L" Journal annals of the rheumatic diseases
35 results on '"Abasolo L"'

2. POS1427 CLINICAL COURSE IN PATIENTS WITH INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES (IPAF): REAL-LIFE DATA FROM A MULTICENTER ILD REGISTRY

Author

Vadillo, C., primary, Nieto, M. A., additional, Sanchez Pernaute, O., additional, Romero, F., additional, Rodriguez, M. J., additional, Freites Nuñez, D., additional, Bonilla, G., additional, Cobo, T. I., additional, Cebrián Méndez, L., additional, Godoy, H., additional, Rio, M. T., additional, and Abasolo, L., additional

Published
2022
Full Text
View/download PDF

3. AB1171 PERSISTENT POST-DISCHARGE SYMPTOMS AFTER COVID-19 IN RHEUMATIC AND MUSCULOSKELETAL DISEASES

Author

Perez-Sancristobal, I., primary, León, L., additional, Álvarez Hernandez, M. P., additional, Madrid García, A., additional, Lopez Pedraza, L., additional, Colomer, J. I., additional, Lerma Lara, S., additional, Lois, P., additional, Mucientes, A., additional, Rodriguez Rodriguez, L., additional, Fernandez, B., additional, and Abasolo, L., additional

Published
2022
Full Text
View/download PDF

4. POS0795 EPIDEMIOLOGY, DIAGNOSIS AND CLINICAL CHARACTERISTICS OF GIANT CELL ARTERITIS IN PATIENTS INCLUDED IN THE ARTESER MULTICENTER STUDY

Author

Sánchez-Costa, J. T., primary, Melero González, R. B., additional, Fernández-Fernández, E., additional, Silva, M. T., additional, Belzunegui Otano, J. M., additional, Moriano, C., additional, Sanchez-Martin, J., additional, Lluch Pons, J., additional, Calvo, I., additional, Aldasoro, V., additional, Abasolo, L., additional, Loricera, J., additional, Ruiz Román, A., additional, Castañeda, S., additional, Moya, P., additional, Garcia Villanueva, M. J., additional, Navarro Angeles, V. A., additional, Galisteo, C., additional, Riveros, A., additional, Román Ivorra, J. A., additional, Labrada, S., additional, Vasques Rocha, M., additional, Iñíguez, C. L., additional, Garcia Gonzalez, M., additional, Molina, C., additional, Alcalde Villar, M., additional, Mas, A. J., additional, De Miguel, E., additional, Narváez, J., additional, González-Gay, M. A., additional, Garrido Puñal, N. P., additional, Estrada, P., additional, and Blanco, R., additional

Published
2022
Full Text
View/download PDF

9. POS1253 MORTALITY RATE RELATED TO COVID - 19 IN RHEUMATIC AND MUSCULOSKELETAL DISEASES (RMDs)

Author

Freites, D., primary, Perez-Sancristobal, I., additional, Lopez Pedraza, L., additional, Álvarez Hernandez, M. P., additional, Hernandez, I., additional, Colomer, J. I., additional, Madrid García, A., additional, Fernandez, B., additional, Vadillo, C., additional, Rodriguez Rodriguez, L., additional, Mucientes, A., additional, León, L., additional, and Abasolo, L., additional

Published
2021
Full Text
View/download PDF

12. AB0290 HERPES ZOSTER INFECTIONS IN RHEUMATOID ARTHRITIS PATIENTS EXPOSED TO BIOLOGICAL AGENTS AND JAK INHIBITORS. REAL-WORLD EVIDENCE.

Author

Freites Nuñez, D., primary, Abasolo, L., additional, Peñuelas, M., additional, Candel, F. J., additional, Font, J., additional, Lois, P., additional, Martinez Prada, C., additional, Fernandez, B., additional, Madrid García, A., additional, Rodriguez Rodriguez, L., additional, Colomer, J. I., additional, and León, L., additional

Published
2020
Full Text
View/download PDF

26. AB1152 Early Intervention in Musculoskeletal Disease Can Reduce Temporary Work Disability

Author

Vela, P., primary, Abasolo, L., additional, Lajas, C., additional, Gil, S., additional, Cuenca, N., additional, Senabre, J.M., additional, Lopez, A., additional, Barros, A., additional, Macia, C., additional, Tejon, P., additional, Aparicio, M., additional, Rosas, J., additional, Perez, T., additional, Valdazo, J.P., additional, Medina, J., additional, Belmonte, M.A., additional, Nolla, J.M., additional, and Jover, J.A., additional

Published
2015
Full Text
View/download PDF

31. Response to: 'Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'' by Aydin et al .

Author

Freites Nuñez DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, Font Urgelles J, Madrid García A, Colomer JI, Jover JA, Fernandez-Gutierrez B, and Abasolo L

Subjects
Humans, Risk Factors, Hospitalization, Hospitals, COVID-19, Arthritis, Rheumatoid, Rheumatic Diseases complications, Rheumatic Diseases epidemiology, Autoimmune Diseases epidemiology
Abstract

Competing Interests: Competing interests: None declared.

Published
2023
Full Text
View/download PDF

32. Response to: 'Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'' by Schulze-Koops et al .

Author

Freites Nuñez DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, Font Urgelles J, Madrid García A, Colomer JI, Jover JA, Fernandez-Gutierrez B, and Abasolo L

Subjects
Humans, Risk Factors, Hospitals, COVID-19, Arthritis, Rheumatoid complications, Arthritis, Rheumatoid drug therapy, Rheumatic Diseases complications, Autoimmune Diseases epidemiology
Abstract

Competing Interests: Competing interests: None declared.

Published
2023
Full Text
View/download PDF

33. EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis.

Author

Boonen A, Putrik P, Marques ML, Alunno A, Abasolo L, Beaton D, Betteridge N, Bjørk M, Boers M, Boteva B, Fautrel B, Guillemin F, Mateus EF, Nikiphorou E, Péntek M, Pimentel Santos F, Severens JL, Verstappen SMM, Walker-Bone K, Wallman JK, Ter Wee MM, Westhovens R, and Ramiro S

Subjects
Advisory Committees, Data Analysis, Europe, Guidelines as Topic, Humans, Research Design, Research Report, Societies, Medical, Arthritis, Employment, Outcome Assessment, Health Care, Work, Work Engagement
Abstract

Background: Clinical studies with work participation (WP) as an outcome domain pose particular methodological challenges that hamper interpretation, comparison between studies and meta-analyses., Objectives: To develop Points to Consider (PtC) for design, analysis and reporting of studies of patients with inflammatory arthritis that include WP as a primary or secondary outcome domain., Methods: The EULAR Standardised Operating Procedures were followed. A multidisciplinary taskforce with 22 experts including patients with rheumatic diseases, from 10 EULAR countries and Canada, identified methodologic areas of concern. Two systematic literature reviews (SLR) appraised the methodology across these areas. In parallel, two surveys among professional societies and experts outside the taskforce sought for additional methodological areas or existing conducting/reporting recommendations. The taskforce formulated the PtC after presentation of the SLRs and survey results, and discussion. Consensus was obtained through informal voting, with levels of agreement obtained anonymously., Results: Two overarching principles and nine PtC were formulated. The taskforce recommends to align the work-related study objective to the design, duration, and outcome domains/measurement instruments of the study (PtC: 1-3); to identify contextual factors upfront and account for them in analyses (PtC: 4); to account for interdependence of different work outcome domains and for changes in work status over time (PtC: 5-7); to present results as means as well as proportions of patients reaching predefined meaningful categories (PtC: 8) and to explicitly report volumes of productivity loss when costs are an outcome (PtC:9)., Conclusion: Adherence to these EULAR PtC will improve the methodological quality of studies evaluating WP., Competing Interests: Competing interests: AB: research grants from Abbvie and Celgene and honoraria for consultancy or speakers honoraria from UCB, Biogen, Sandoz, Eli Lilly and Galapagos (all to her department); EN has received speaker honoraria/participated in advisory boards for Celltrion, Pfizer, Sanofi, Gilead, AbbVie and Lilly; FPS: research grant from AbbVie, Novartis; consultancy or speaking fees: AbbVie, Angelini, AstraZeneca, Biogen, Eli Lilly, Laboratórios Vitória, MSD, Novartis, Tecnimed, UCB; SR: research grant from MSD; consultancy or speaking fees: AbbVie, Eli Lilly, MSD, Novartis, Sanofi, UCB; JKW: consultancy fees from Celgene, Eli Lilly, Novartis; RW: consultancy and speakers bureau Celltrion and Galapagos/Gilead., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2021
Full Text
View/download PDF

34. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases.

Author

Freites Nuñez DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, Font Urgelles J, Madrid García A, Colomer JI, Jover JA, Fernandez-Gutierrez B, and Abasolo L

Subjects
Age Factors, Aged, Aged, 80 and over, Ambulatory Care, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid epidemiology, Autoimmune Diseases drug therapy, Betacoronavirus, COVID-19, Diabetes Mellitus epidemiology, Female, Glucocorticoids therapeutic use, Heart Diseases epidemiology, Humans, Hypertension epidemiology, Length of Stay statistics & numerical data, Longitudinal Studies, Lung Diseases epidemiology, Lupus Erythematosus, Systemic drug therapy, Lupus Erythematosus, Systemic epidemiology, Male, Middle Aged, Mixed Connective Tissue Disease drug therapy, Mixed Connective Tissue Disease epidemiology, Multivariate Analysis, Pandemics, Polymyalgia Rheumatica drug therapy, Polymyalgia Rheumatica epidemiology, Protective Factors, Rheumatic Diseases drug therapy, Risk Factors, SARS-CoV-2, Sex Factors, Sjogren's Syndrome drug therapy, Sjogren's Syndrome epidemiology, Spain epidemiology, Spondylarthropathies drug therapy, Spondylarthropathies epidemiology, Tumor Necrosis Factor Inhibitors therapeutic use, Autoimmune Diseases epidemiology, Coronavirus Infections therapy, Hospitalization statistics & numerical data, Pneumonia, Viral therapy, Rheumatic Diseases epidemiology
Abstract

Objectives: To describe patients with autoimmune inflammatory rheumatic diseases (AIRD) who had COVID-19 disease; to compare patients who required hospital admission with those who did not and assess risk factors for hospital admission related to COVID-19., Methods: An observational longitudinal study was conducted during the pandemic peak of severe acute respiratory syndrome coronavirus 2 (1 March 2020 to 24 April). All patients attended at the rheumatology outpatient clinic of a tertiary hospital in Madrid, Spain with a medical diagnosis of AIRD and with symptomatic COVID-19 were included. The main outcome was hospital admission related to COVID-19. The covariates were sociodemographic, clinical and treatments. We ran a multivariable logistic regression model to assess risk factors for the hospital admission., Results: The study population included 123 patients with AIRD and COVID-19. Of these, 54 patients required hospital admission related to COVID-19. The mean age on admission was 69.7 (15.7) years, and the median time from onset of symptoms to hospital admission was 5 (3-10) days. The median length of stay was 9 (6-14) days. A total of 12 patients died (22%) during admission. Compared with outpatients, the factors independently associated with hospital admission were older age (OR: 1.08; p=0.00) and autoimmune systemic condition (vs chronic inflammatory arthritis) (OR: 3.55; p=0.01). No statistically significant findings for exposure to disease-modifying antirheumatic drugs were found in the final model., Conclusion: Our results suggest that age and having a systemic autoimmune condition increased the risk of hospital admission, whereas disease-modifying antirheumatic drugs were not associated with hospital admission., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2020
Full Text
View/download PDF

35. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases.

Author

Pablos JL, Abasolo L, Alvaro-Gracia JM, Blanco FJ, Blanco R, Castrejón I, Fernandez-Fernandez D, Fernandez-Gutierrez B, Galindo-Izquierdo M, Gonzalez-Gay MA, Manrique-Arija S, Mena Vázquez N, Mera Varela A, Retuerto M, and Seijas-Lopez A

Subjects
Adult, Age Distribution, Aged, Antirheumatic Agents adverse effects, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid epidemiology, Arthritis, Rheumatoid virology, Autoimmune Diseases drug therapy, Autoimmune Diseases virology, COVID-19, Coronavirus Infections diagnosis, Coronavirus Infections virology, Female, Humans, Lupus Erythematosus, Systemic drug therapy, Lupus Erythematosus, Systemic epidemiology, Lupus Erythematosus, Systemic virology, Male, Middle Aged, Pandemics, Pneumonia, Viral diagnosis, Pneumonia, Viral virology, Polymerase Chain Reaction, Prevalence, Retrospective Studies, Rheumatic Diseases drug therapy, Rheumatic Diseases virology, SARS-CoV-2, Spain epidemiology, Autoimmune Diseases epidemiology, Betacoronavirus, Coronavirus Infections epidemiology, Hospitalization statistics & numerical data, Pneumonia, Viral epidemiology, Rheumatic Diseases epidemiology
Abstract

Background: The susceptibility of patients with rheumatic diseases and the risks or benefits of immunosuppressive therapies for COVID-19 are unknown., Methods: We performed a retrospective study with patients under follow-up in rheumatology departments from seven hospitals in Spain. We matched updated databases of rheumatology patients with severe acute respiratory syndrome coronavirus 2-positive PCR tests performed in the hospital to the same reference populations. Rates of PCR+ confirmed COVID-19 were compared among groups., Results: Patients with chronic inflammatory diseases had 1.32-fold higher prevalence of hospital PCR+ COVID-19 than the reference population (0.76% vs 0.58%). Patients with systemic autoimmune or immune-mediated disease (AI/IMID) showed a significant increase, whereas patients with inflammatory arthritis (IA) or systemic lupus erythematosus did not. COVID-19 cases in some but not all diagnostic groups had older ages than cases in the reference population. Patients with IA on targeted-synthetic or biological disease-modifying antirheumatic drugs (DMARDs), but not those on conventional-synthetic DMARDs, had a greater prevalence despite a similar age distribution., Conclusion: Patients with AI/IMID show a variable risk of hospital-diagnosed COVID-19. Interplay of ageing, therapies and disease-specific factors seem to contribute. These data provide a basis to improve preventive recommendations to rheumatic patients and to analyse the specific factors involved in COVID-19 susceptibility., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results